학술논문
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
Document Type
article
Author
Anne-Sophie Chretien; Cyril Fauriat; Florence Orlanducci; Claire Galseran; Jerome Rey; Gaelle Bouvier Borg; Emmanuel Gautherot; Samuel Granjeaud; Jean-François Hamel-Broza; Clemence Demerle; Norbert Ifrah; Catherine Lacombe; Pascale Cornillet-Lefebvre; Jacques Delaunay; Antoine Toubert; Emilie Gregori; Herve Luche; Marie Malissen; Christine Arnoulet; Jacques A. Nunes; Norbert Vey; Daniel Olive
Source
Frontiers in Immunology, Vol 8 (2017)
Subject
Language
English
ISSN
1664-3224
Abstract
Accumulating evidence highlights natural killer (NK) cell parameters as potential prognostic factors in cancer patients, which provides a strong rationale for developing therapeutic strategies aiming at restoring NK cell. However, reaching this point warrants better characterization of tumor-induced NK cell alterations. Our group recently reported heterogeneous NK maturation in acute myeloid leukemia (AML) patients. However, the clinical significance of such observations remained to be assessed on a larger cohort of patients. NK maturation based on expression of CD56, CD57, and KIR was assessed by flow cytometry in newly diagnosed AML patients (N = 87 patients from GOELAMS-LAM-IR-2006 multicenter trial). Clinical outcome was evaluated with regard to NK maturation profiles. Unsupervised integrated analysis of NK maturation markers confirmed the existence of three distinct groups of patients [hypomaturation (24.1%), intermediate maturation (66.7%), and hypermaturation (9.2%)]. In univariate analysis, significant differences in overall survival (OS) (P = 0.0006) and relapse-free survival (RFS) (P